Metropolitan Life Insurance CO Spring Works Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$36.5 - $52.5 $7,519 - $10,815	-206 Reduced 5.31%	3,670 $180,000
Q4 2023 Feb 14, 2024	BUY	$18.94 - $37.24 $9,697 - $19,066	512 Added 15.22%	3,876 $141,000
Q3 2023 Nov 14, 2023	BUY	$23.12 - $31.38 $4,138 - $5,617	179 Added 5.62%	3,364 $77,000
Q2 2023 Aug 10, 2023	BUY	$23.15 - $32.71 $73,732 - $104,181	3,185 New	3,185 $83,000
Q4 2022 Jun 14, 2023	BUY	$21.73 - $28.72 $46,806 - $61,862	2,154 New	2,154 $56 Million
Q4 2022 Mar 30, 2023	BUY	$21.73 - $28.72 $5,389 - $7,122	248 Added 13.01%	2,154 $56,000
Q4 2022 Feb 15, 2023	BUY	$21.73 - $28.72 $5,389 - $7,122	248 Added 13.01%	2,154 $56,000
Q3 2022 Jun 14, 2023	BUY	$24.1 - $39.66 $45,934 - $75,591	1,906 New	1,906 $54.4 Million
Q2 2022 Jun 20, 2023	BUY	$18.36 - $60.07 $34,994 - $114,493	1,906 New	1,906 $46,000
Q1 2022 Jun 20, 2023	BUY	$48.97 - $65.46 $93,336 - $124,766	1,906 New	1,906 $107,000
Q1 2022 Mar 30, 2023	SELL	$48.97 - $65.46 $270,755 - $361,928	-5,529 Reduced 74.36%	1,906 $107,000
Q1 2022 May 12, 2022	SELL	$48.97 - $65.46 $270,755 - $361,928	-5,529 Reduced 74.36%	1,906 $108,000
Q4 2021 Jun 21, 2023	BUY	$53.3 - $75.84 $396,285 - $563,870	7,435 New	7,435 $460,000
Q4 2021 Mar 30, 2023	SELL	$53.3 - $75.84 $34,325 - $48,840	-644 Reduced 7.97%	7,435 $460,000
Q4 2021 Feb 15, 2022	SELL	$53.3 - $75.84 $34,325 - $48,840	-644 Reduced 7.97%	7,435 $461,000
Q3 2021 Jun 21, 2023	BUY	$62.66 - $88.26 $506,230 - $713,052	8,079 New	8,079 $512,000
Q2 2021 Mar 30, 2023	BUY	$67.45 - $85.63 $110,618 - $140,433	1,640 Added 25.47%	8,079 $665,000
Q2 2021 Aug 16, 2021	BUY	$67.45 - $85.63 $544,523 - $691,290	8,073 Added 134550.0%	8,079 $666,000
Q1 2021 Jun 26, 2023	BUY	$65.1 - $93.59 $419,178 - $602,626	6,439 New	6,439 $474 Million
Q1 2021 Mar 30, 2023	SELL	$65.1 - $93.59 $14,126 - $20,309	-217 Reduced 3.26%	6,439 $473,000
Q1 2021 May 14, 2021	SELL	$65.1 - $93.59 $432,914 - $622,373	-6,650 Reduced 99.91%	6 $474,000
Q4 2020 Jun 22, 2023	BUY	$48.36 - $77.92 $321,884 - $518,635	6,656 New	6,656 $482,000
Q3 2020 Jun 26, 2023	BUY	$36.14 - $51.99 $240,547 - $346,045	6,656 New	6,656 $317,000
Q2 2020 Jun 26, 2023	BUY	$22.98 - $48.57 $152,954 - $323,281	6,656 New	6,656 $279,000
Q2 2020 Mar 30, 2023	BUY	$22.98 - $48.57 $71,973 - $152,121	3,132 Added 88.88%	6,656 $279,000
Q2 2020 Aug 14, 2020	BUY	$22.98 - $48.57 $71,973 - $152,121	3,132 Added 88.88%	6,656 $280,000
Q1 2020 Jul 12, 2023	BUY	$20.44 - $41.21 $72,030 - $145,224	3,524 New	3,524 $95,000
Q1 2020 Mar 30, 2023	SELL	$20.44 - $41.21 $47,747 - $96,266	-2,336 Reduced 39.86%	3,524 $95,000
Q1 2020 May 15, 2020	SELL	$20.44 - $41.21 $47,747 - $96,266	-2,336 Reduced 39.86%	3,524 $95,000
Q4 2019 Jul 12, 2023	BUY	$17.74 - $39.52 $103,956 - $231,587	5,860 New	5,860 $225,000
Q4 2019 Mar 30, 2023	BUY	$17.74 - $39.52 $65,744 - $146,461	3,706 Added 172.05%	5,860 $225,000
Q4 2019 Feb 14, 2020	BUY	$17.74 - $39.52 $103,956 - $231,587	5,860 New	5,860 $226,000

Others Institutions Holding SWTX

# of Institutions

237

Shares Held

68.9M

Call Options Held

144K

Put Options Held

257K

Vanguard Group Inc Valley Forge, PA

6.71M
Shares

$244 Million
0.0% of portfolio
Black Rock Inc. New York, NY

5.62M
Shares

$204 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

3.84M
Shares

$140 Million
4.54% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.52M
Shares

$128 Million
0.01% of portfolio
Boxer Capital, LLC San Diego, CA

3.42M
Shares

$124 Million
5.82% of portfolio

View Full List

About SpringWorks Therapeutics, Inc.

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.27B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

More about SWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account